title: CMT-3. CollaGenex.
abstract: CMT-3 is an orally active matrix metalloprotease inhibitor, and one of a series of inhibitors of multiple proteases and cytokines, under development by CollaGenex. The compound is currently undergoing phase II trials for the potential treatment of cancer, in particular metastatic cancer and HIV-related Kaposi's sarcoma.
authors.affiliation: Vanderbilt University Medical Center, Department of Cancer Biology, 736 Preston Research Building, 23rd and Pierce Avenues, Nashville, TN 37232-6840, USA. barbara.fingleton@Vanderbilt.Edu
authors.forename: Barbara
authors.initials: B
authors.lastname: Fingleton
mesh_terms: D000818:Animals; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D015507:Drugs, Investigational / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D004791:Enzyme Inhibitors / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D061965:Matrix Metalloproteinase Inhibitors; D020782:Matrix Metalloproteinases / Q000378:metabolism; D009369:Neoplasms / Q000188:drug therapy* / Q000201:enzymology; D013678:Technology, Pharmaceutical / Q000379:methods; D013754:Tetracyclines / Q000009:adverse effects / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D015507:Drugs, Investigational; D004791:Enzyme Inhibitors; D061965:Matrix Metalloproteinase Inhibitors; D013754:Tetracyclines; C117155:tetracycline CMT-3; D020782:Matrix Metalloproteinases